---

NICE consults on preliminary decision not to recommend everolimus for advanced renal cell carcinoma
In draft guidance, published today (9 February 2010), the National Institute for Health and Clinical Excellence (NICE) has been unable to recommend everolimus (afinitor, Novartis) for the second line treatment of advanced renal cell carcinoma. >>

---

Novartis Oncology concerned by initial NICE decision to deny advanced kidney cancer patients effective treatment with Afinitor® (everolimus)
... >>

---

Drug proved to prolong kidney cancer patients' lives deemed too expensive by NICE
The National Institute for Health and Clinical Excellence ruled the drug Everolimus (Afinitor) too expensive to fund despite the fact that it’s a proven life prolonging drug for kidney cancer patients. This is especially pertinent to kidney cancer patients as it’s a type of cancer that is very difficult to treat. >>

---

News articles relating to N.I.C.E. decision to deny Afinitor
News Items >>

---

Cancer care plans could cut costs

Health Service Journal, 20 January 2010

http://www.hsj.co.uk/5010531.article  >>

---

Countrywide stores raise funds for charity
By Robert Hale, Ledbury Reporter >>

---

Technology Appraisal at NICE - EVEROLIMUS ( AFINITOR) - by Bill Savage
I represented The James Whale Fund at this review of the new drug Everolimus in the NICE offices at Manchester as a " patient expert ".  The review was the main meeting which decides whether to recommend that this new drug is funded by the NHS. >>